FDA Approves Idelalisib (Zydelig) for Leukemia and Lymphoma
The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for people with relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma (another type of non-Hodgkin lymphoma). Learn more here.
FDA Approves Imbruvica (Ibrutinib) for Chronic Lymphocytic Leukemia
The US Food and Drug Administration has approved the use of Imbruvica (ibrutinib) to treat some people with chronic lymphocytic leukemia (CLL).
Study Shows Experimental Drug Idelalisib Effective Against Chronic Lymphocytic Leukemia
A study of idelalisib finds that this experimental targeted therapy drug may effectively treat chronic lymphocytic leukemia (CLL) patients without the need for chemotherapy.
Drug Shows Promise for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Ibrutinib, a new drug under development, is showing promise as a treatment for mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to new studies.